W

hen a French drug trial killed one test subject last year, many observers immediately questioned why such risks hadn’t been flagged by earlier experiments.

The drug, a potential painkiller in development by Bial, led to brain death in one case and hospitalization in five others.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X